Literature DB >> 24569537

Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.

Y C Fierz1, R Kenmeni1, A Gonthier1, F Lier1, F Pralong1, P Coti Bertrand1.   

Abstract

Malnutrition may result in a phosphate-deficient state owing to a chronically insufficient phosphate intake. Concomitant iron deficiency is common and often supplemented by the intravenous route. It is not widely recognized that some parenteral iron formulations can induce hypophosphatemia. Herein we report a case of a severe and symptomatic hypophosphatemia (0.18 mM, normal range 0.8-1.4 mM) associated with an inappropriately reduced tubular reabsorption of phosphate (33%, norm >95%) in a malnourished patient with anorexia/bulimia who received 2 × 500 mg iron carboxymaltose (FCM) intravenously. Despite intravenous and oral phosphate supplements, it required 2 months to achieve a normal serum phosphate level. Our case demonstrates that in a chronically malnourished and phosphate-deficient state intravenous FCM could potentially be dangerous. If this form of iron application cannot be avoided, phosphate supplementation before and after iron infusion as well as close monitoring of phosphate levels are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569537     DOI: 10.1038/ejcn.2014.20

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  10 in total

1.  Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.

Authors:  Laila-Yasmin Mani; Ghaleb Nseir; Jean-Pierre Venetz; Manuel Pascual
Journal:  Transplantation       Date:  2010-10-15       Impact factor: 4.939

2.  Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial.

Authors:  Paul Vaucher; Pierre-Louis Druais; Sophie Waldvogel; Bernard Favrat
Journal:  CMAJ       Date:  2012-07-09       Impact factor: 8.262

Review 3.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

4.  Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.

Authors:  M Okada; K Imamura; M Iida; T Fuchigami; T Omae
Journal:  Klin Wochenschr       Date:  1983-01-17

Review 5.  Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment.

Authors:  R Subramanian; R Khardori
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

6.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Authors:  Myles Wolf; Todd A Koch; David B Bregman
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

7.  Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.

Authors:  David B Van Wyck; Antoinette Mangione; John Morrison; Phillip Earl Hadley; Judi A Jehle; Lawrence Tim Goodnough
Journal:  Transfusion       Date:  2009-07-22       Impact factor: 3.157

8.  FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

Authors:  Belinda J Schouten; Penelope J Hunt; John H Livesey; Chris M Frampton; Steven G Soule
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

9.  Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia.

Authors:  Iftikhar Hussain; Jessica Bhoyroo; Angelia Butcher; Todd A Koch; Andy He; David B Bregman
Journal:  Anemia       Date:  2013-08-29

10.  Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.

Authors:  Saroj Vadhan-Raj; William Strauss; David Ford; Kristine Bernard; Ralph Boccia; Joe Li; Lee F Allen
Journal:  Am J Hematol       Date:  2013-09-30       Impact factor: 10.047

  10 in total
  13 in total

1.  Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.

Authors:  Palle Bager; Christian L Hvas; Jens F Dahlerup
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

Review 2.  Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature.

Authors:  Ramy H Bishay; Kirtan Ganda; Markus J Seibel
Journal:  Ther Adv Endocrinol Metab       Date:  2016-11-21       Impact factor: 3.565

3.  Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.

Authors:  Rebecca Frazier; Alexander Hodakowski; Xuan Cai; Jungwha Lee; Anaadriana Zakarija; Brady Stein; Valentin David; Myles Wolf; Tamara Isakova; Rupal Mehta
Journal:  Bone       Date:  2020-07-28       Impact factor: 4.398

Review 4.  Intravenous iron administration and hypophosphatemia in clinical practice.

Authors:  S Hardy; X Vandemergel
Journal:  Int J Rheumatol       Date:  2015-04-27

5.  Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature.

Authors:  Xavier Vandemergel; Frédéric Vandergheynst
Journal:  Case Rep Endocrinol       Date:  2014-11-13

6.  Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.

Authors:  Benedikt Schaefer; Philipp Würtinger; Armin Finkenstedt; Vickie Braithwaite; André Viveiros; Maria Effenberger; Irene Sulzbacher; Alexander Moschen; Andrea Griesmacher; Herbert Tilg; Wolfgang Vogel; Heinz Zoller
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 7.  Refeeding syndrome in the frail elderly population: prevention, diagnosis and management.

Authors:  Emilie Aubry; Natalie Friedli; Philipp Schuetz; Zeno Stanga
Journal:  Clin Exp Gastroenterol       Date:  2018-07-10

8.  Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose.

Authors:  Wendy Fang; Lawrence P McMahon; Stephen Bloom; Mayur Garg
Journal:  JGH Open       Date:  2019-03-27

Review 9.  Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.

Authors:  John A Glaspy; Michelle Z Lim-Watson; Michael A Libre; Swagata S Karkare; Nandini Hadker; Aleksandra Bajic-Lucas; William E Strauss; Naomi V Dahl
Journal:  Ther Clin Risk Manag       Date:  2020-04-08       Impact factor: 2.423

Review 10.  Management of Refeeding Syndrome in Medical Inpatients.

Authors:  Emilie Reber; Natalie Friedli; Maria F Vasiloglou; Philipp Schuetz; Zeno Stanga
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.